Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ: PEPG )

8.700 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,133
Open 8.720
Bid (Size) 8.620 (3)
Ask (Size) 8.700 (17)
Prev. Close 8.700
Today's Range 8.600 - 8.860
52wk Range 3.720 - 19.30
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
From PepGen Inc.
Via Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
Exposures Product Safety

Performance

YTD
+22.71%
+22.71%
1 Month
-3.12%
-3.12%
3 Month
-50.54%
-50.54%
6 Month
-25.77%
-25.77%
1 Year
+61.71%
+61.71%

More News

Read More
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
From PepGen Inc.
Via Business Wire
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
From PepGen Inc.
Via Business Wire
PEPG Stock Earnings: PepGen Misses EPS for Q2 2024
Via InvestorPlace
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
Via InvestorPlace
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
From PepGen Inc.
Via Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
Via InvestorPlace
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher
Via Benzinga
Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via Business Wire
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
From PepGen Inc.
Via Business Wire
PepGen Announces Executive Team Promotions
From PepGen Inc.
Via Business Wire
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Insiders Buying GameStop And 2 Other Stocks
Via Benzinga
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.